{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,2]],"date-time":"2026-06-02T08:49:28Z","timestamp":1780390168907,"version":"3.54.1"},"reference-count":23,"publisher":"Wiley","issue":"10","license":[{"start":{"date-parts":[[2023,5,21]],"date-time":"2023-05-21T00:00:00Z","timestamp":1684627200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["accp1.onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Clinical Pharm in Drug Dev"],"published-print":{"date-parts":[[2023,10]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Atogepant, an oral calcitonin gene\u2010related peptide receptor antagonist, and topiramate, a commonly used oral antiepileptic, are approved as preventive migraine treatments. Given the distinct mechanisms of action of these treatments, it is possible that they may be coprescribed for migraine. This open\u2010label, single\u2010center, 2\u2010cohort, phase 1 trial evaluated the potential pharmacokinetic (PK) 2\u2010way drug\u2013drug interactions (DDIs), safety, and tolerability of atogepant and topiramate in healthy adults. Participants received atogepant 60\u00a0mg once daily and topiramate 100\u00a0mg twice daily. Cohort 1 (N\u00a0=\u00a028) evaluated the effect of topiramate on the PK of atogepant; cohort 2 (N\u00a0=\u00a025) evaluated the effect of atogepant on the PK of topiramate. Potential DDIs were assessed using geometric mean ratios and 90% confidence intervals calculated for maximum plasma drug concentration at steady state (C<jats:sub>max,ss<\/jats:sub>) and area under the plasma concentration\u2013time curve during the dosing interval at steady state (AUC<jats:sub>0\u2212tau,ss<\/jats:sub>). Additional PK parameters were assessed. Atogepant AUC<jats:sub>0\u2212tau,ss<\/jats:sub> and C<jats:sub>max,ss<\/jats:sub> decreased by 25% and 24%, respectively, with topiramate coadministration. Topiramate AUC<jats:sub>0\u2212tau,ss<\/jats:sub> and C<jats:sub>max,ss<\/jats:sub> decreased by 5% and 6%, respectively, with atogepant coadministration. The 25% reduction in atogepant exposure when coadministered with topiramate is not considered to be clinically relevant and would not require dose adjustments.<\/jats:p>","DOI":"10.1002\/cpdd.1267","type":"journal-article","created":{"date-parts":[[2023,5,21]],"date-time":"2023-05-21T16:25:00Z","timestamp":1684686300000},"page":"1013-1021","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":9,"title":["Pharmacokinetics and Safety of Coadministered Atogepant and Topiramate in Healthy Participants: A Phase 1, Open\u2010Label, Drug\u2013Drug Interaction Study"],"prefix":"10.1002","volume":"12","author":[{"given":"Ramesh","family":"Boinpally","sequence":"first","affiliation":[{"name":"AbbVie Madison New Jersey USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Danielle","family":"McGeeney","sequence":"additional","affiliation":[{"name":"AbbVie Madison New Jersey USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lisa","family":"Borbridge","sequence":"additional","affiliation":[{"name":"AbbVie Irvine California USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joel","family":"Trugman","sequence":"additional","affiliation":[{"name":"AbbVie Madison New Jersey USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2023,5,21]]},"reference":[{"issue":"4","key":"e_1_2_11_2_1","first-page":"973","article-title":"Preventive migraine treatment","volume":"21","author":"Silberstein SD","year":"2015","journal-title":"Continuum (Minneap Minn)"},{"key":"e_1_2_11_3_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2035908"},{"issue":"1","key":"e_1_2_11_4_1","first-page":"72","article-title":"Medications for migraine prophylaxis","volume":"73","author":"Modi S","year":"2006","journal-title":"Am Fam Physician"},{"key":"e_1_2_11_5_1","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0b013e3182535d20"},{"key":"e_1_2_11_6_1","doi-asserted-by":"publisher","DOI":"10.1097\/j.pain.0000000000000831"},{"key":"e_1_2_11_7_1","doi-asserted-by":"publisher","DOI":"10.1111\/bcp.12618"},{"key":"e_1_2_11_8_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(17)30083-2"},{"key":"e_1_2_11_9_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamaneurol.2017.3859"},{"key":"e_1_2_11_10_1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2018.4853"},{"key":"e_1_2_11_11_1","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000009169"},{"key":"e_1_2_11_12_1","unstructured":"Pozo\u2010RosichP AilaniJ AshinaM et\u00a0al.Atogepant for the preventive treatment of chronic migraine: results from the PROGRESS phase 3 trial [poster].Presented at: PAINWeek 2022: The National Conference on Pain for Frontline Practitioners; September 6\u20139.Las Vegas NV USA;2022."},{"key":"e_1_2_11_13_1","doi-asserted-by":"publisher","DOI":"10.1002\/cpdd.940"},{"key":"e_1_2_11_14_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40261-021-01034-5"},{"key":"e_1_2_11_15_1","doi-asserted-by":"publisher","DOI":"10.2217\/pmt-2021-0073"},{"key":"e_1_2_11_16_1","doi-asserted-by":"publisher","DOI":"10.1111\/head.14053"},{"key":"e_1_2_11_17_1","doi-asserted-by":"publisher","DOI":"10.1001\/archneur.61.4.490"},{"key":"e_1_2_11_18_1","doi-asserted-by":"publisher","DOI":"10.1592\/phco.26.3.375"},{"key":"e_1_2_11_19_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.0013-9580.2003.06203.x"},{"key":"e_1_2_11_20_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1527-3458.2008.00041.x"},{"key":"e_1_2_11_21_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40265-021-01644-5"},{"key":"e_1_2_11_22_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40261-022-01130-0"},{"key":"e_1_2_11_23_1","doi-asserted-by":"publisher","DOI":"10.1002\/jcph.1610"},{"issue":"1636","key":"e_1_2_11_24_1","first-page":"169","article-title":"Atogepant (Qulipta) for migraine prevention","volume":"63","year":"2021","journal-title":"Med Lett Drugs Ther"}],"container-title":["Clinical Pharmacology in Drug Development"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/accp1.onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/cpdd.1267","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,3]],"date-time":"2023-10-03T02:41:01Z","timestamp":1696300861000},"score":1,"resource":{"primary":{"URL":"https:\/\/accp1.onlinelibrary.wiley.com\/doi\/10.1002\/cpdd.1267"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,5,21]]},"references-count":23,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2023,10]]}},"alternative-id":["10.1002\/cpdd.1267"],"URL":"https:\/\/doi.org\/10.1002\/cpdd.1267","archive":["Portico"],"relation":{},"ISSN":["2160-763X","2160-7648"],"issn-type":[{"value":"2160-763X","type":"print"},{"value":"2160-7648","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,5,21]]},"assertion":[{"value":"2023-01-30","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-04-17","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-05-21","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}